Search hospitals > Ohio > Cleveland
Cleveland Clinic
Claim this profileCleveland, Ohio 44106
Global Leader in Parotid Gland Cancer
Global Leader in Cancer
Conducts research for Adult T-Cell Leukemia/Lymphoma
Conducts research for Heart Failure
Conducts research for Relapse
3239 reported clinical trials
285 medical researchers
Summary
Cleveland Clinic is a medical facility located in Cleveland, Ohio. This center is recognized for care of Parotid Gland Cancer, Cancer, Adult T-Cell Leukemia/Lymphoma, Heart Failure, Relapse and other specialties. Cleveland Clinic is involved with conducting 3,239 clinical trials across 2,535 conditions. There are 285 research doctors associated with this hospital, such as Rabi Hanna, Peter Rose, MD, Sabine s Coppieters, MD, and David Peereboom, MD.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Cancer
Global LeaderStage IV
Stage III
Stage I
Top PIs
Rabi HannaCleveland Clinic Foundation8 years of reported clinical research
Expert in Cancer
Expert in Adult T-Cell Leukemia/Lymphoma
51 reported clinical trials
118 drugs studied
Peter Rose, MDCleveland Clinic Foundation2 years of reported clinical research
Expert in Ovarian Cancer
Expert in Cervical Adenocarcinoma
25 reported clinical trials
50 drugs studied
Sabine s Coppieters, MDInvestigator site 2 - US00100873 years of reported clinical research
Studies Myasthenia Gravis
Studies Muscle Weakness
25 reported clinical trials
13 drugs studied
David Peereboom, MDCleveland Clinic6 years of reported clinical research
Expert in Glioblastoma
Studies Brain Tumor
20 reported clinical trials
32 drugs studied
Clinical Trials running at Cleveland Clinic
Lung Cancer
Ovarian Cancer
Cancer
Multiple Myeloma
Prostate Cancer
Testicular cancer
Acute Lymphoblastic Leukemia
Obesity
Parotid Gland Cancer
Breast Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Cleveland Clinic?
Where is Cleveland Clinic located?
Who should I call to ask about financial aid or insurance network?
What insurance does Cleveland Clinic accept?
What awards or recognition has Cleveland Clinic received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.